FINWIRES · TerminalLIVE
FINWIRES

Emergent BioSolutions Signs $50 Million Contract to Support SAB Biotherapeutics' Lead Program

作者

-- Emergent BioSolutions (EBS) said Wednesday it has signed a $50 million multi-year agreement with SAB Biotherapeutics (SABS) to help advance SAB-142 lead program in clinical development for autoimmune type 1 diabetes.

Under the agreement, $36 million is contingent on future regulatory approval and downstream milestones, according to a statement.

Emergent BioSolutions will provide end-to-end development and manufacturing services that are compliant with current good manufacturing practices, the company said.

Price: $8.17, Change: $-0.07, Percent Change: -0.79%

相關文章

Australia

瑞穗證券將Apellis Pharmaceuticals的目標價從20美元上調至41美元，維持「中性」評等。

根據FactSet調查的分析師數據，Apellis Pharmaceuticals (APLS) 的平均評級為“持有”，平均目標價為40.82美元。 （報道北美、亞洲和歐洲主要銀行及研究機構的股票、商品和經濟研究。研究機構可透過以下連結聯絡我們：https://www..com/contact-us）Price: $40.95, Change: $-0.05, Percent Change: -0.11%

$APLS
Research

瑞穗證券將TERNS Pharmaceuticals的評級從“跑贏大盤”下調至“中性”，並將目標價從54美元下調至53美元。

根據 FactSet 調查的分析師的評價，Terns Pharmaceuticals (TERN) 的平均評級為“持有”，平均目標價為 53 美元。

$TERN
Australia

瑞穗證券將Harmony Biosciences的目標股價從46美元下調至50美元，維持「跑贏大盤」評級。

根據FactSet調查的分析師報告，Harmony Biosciences (HRMY) 的平均評級為“增持”，平均目標價為43美元。 （報道北美、亞洲和歐洲主要銀行及研究機構的股票、商品和經濟研究。研究機構可透過以下連結聯絡我們：https://www..com/contact-us）Price: $31.07, Change: $-0.09, Percent Change: -0.29%

$HRMY